Bristol-Myers Squibb Shares Intellectual Property Rights Of HIV Drug With Medicines Patent Pool

“Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries,” Reuters reports. The licensing deal between the Medicines Patent Pool (MPP) and Bristol “will enable generic drug firms around the world to produce affordable versions of atazanavir, [sold] under the brand name Reyataz, and to combine it with other medicines to make treatment easier,” the news agency notes (Hirschler, 12/12). “This is the MPP’s first agreement covering a [WHO]-preferred second-line therapy. The WHO estimates there will be over one million people on second-line treatment by 2016, and many more will need access to these therapies,” according to an MPP press release (12/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.